Immunization

Johnson & Johnson single-dose COVID-19 vaccine candidate induces durable immune response in participants aged 18 to 55 years; results support further development.

What are the implications of the global emergence of SARS-CoV-2 variants in terms of disease severity and vaccine and treatment efficacy?

Recommendations address the role of clinicians as vaccinators and stress as essential communication and collaboration with patients' primary care team.

The 2 FDA-approved COVID-19 vaccines are similarly effective but also very different in a number of ways that will affect distribution.

A new Kaiser Family Foundation survey project found 85% of respondents trust their regular healthcare provider for information COVID-19 vaccination. PCPs, read more.

Vaccination against COVID-19 for US healthcare personnel began on December 14, 2020; the same day, CDC hosted a webinar on how to ensure HCP health and safety during this period.

Early COVID-19 vaccine demand will far exceed supply and so states have been refining distribution plans for months. Here is a topline review of what to expect.

COVID-19 cases are surging across the country as the US heads into holiday season. Counsel patients on staying safe and keep these billing codes very close at hand.

Moderna announced safety and efficacy data from the phase 3 COVE trial that found mRNA-1273 94.5% effective in preventing infection with SARS-CoV-2.

The new guideline section stresses that testing is the only way to accurately discriminate between the 2 viruses and advises on influenza vaccination and treatment.

The FDA has issued guidance for sponsors of requests for EUA for COVID-19 vaccines including details on clinical trial data required to support award of EUA.

CEOs of 9 drug companies involved in COVID-19 vaccine development signed a pledge ensuring that sound science and ethics will guide the process.

The CDC estimates delivery of a record 194 to 198 million doses of influenza vaccine this year. The primary care imperative: vaccinate, vaccinate, vaccinate.

The AstraZeneca-Oxford University investigational coronavirus disease 2019 (COVID-19) vaccine candidate, has expanded into a phase 3 clinical trial.

A Harris Poll finds Americans want a US-approved COVID-19 vaccine allocated here first, the rest of the world next, and our most vulnerable take priority.

VIDEO: NIH-funded infectious disease expert discusses convalescent plasma, remdesivir, corticosteroids, and the COVID-19 vaccine timeline.

Groups at high risk for influenza and its complications were less likely to receive vaccination while hospitalized vs the general population, according to a new study.

The COVID-19 pandemic makes timely catch-up vaccination against all vaccine-preventable diseases essential. Try these 5 questions on CDC recommendations.

Pneumococcal vaccine should still be given to adults aged ≥65 years, but no longer to all adults in that population. Find out what you know - and what you may need to know.

The ACIP, once more, revised its recommendations for administration of pneumococcal vaccination among adults aged ≥65 years. Is there a lesson learned here?

A pulmonary and critical care specialist identifies 4 factors that will, in part, determine the severity of the 2020-2021 flu season and that can inform preparation.

There are nearly 30 COVID-19 vaccine candidates in human trials. Confused? Here's a short primer on the old and new development platforms and the pros and cons.

Communicating the importance of immunization to wary patients is key during the COVID-19 pandemic. Check out our new slideshow for the most recent CDC guidance for clinicians.

Flu vaccination coverage for adults is highest in West Virginia, lowest in Louisiana. Where does your state rank on flu, HPV, pneumococcal and 5 other vaccines?

A trio of experts will discuss the prospects of a handful of COVID-19 vaccine candidates which are entering phase 3 trials.

COVID-19 vaccine hopeful mRNA-1273 will be administered to 30,000 trial volunteers at 89 US research sites.

University of Oxford researchers will recruit more than 10 000 participants and evaluate groups of young and elderly to evaluate immune response across the lifespan.

Phase I clinical trials of the adjuvanted vaccine against the SARS-CoV-2 virus could begin in the second half of 2020, according to the companies.

From measles resurgence to new CVD guidelines, refresh your memory of this year’s highlights with our quiz on the most-read content on Patient Care®.

The rules for pneumococcal vaccination can seem a little arbitrary. See what you know about the ACIP rationale behind these 5 recommendations for PCV13 and PPSV23.